BD

BD (Becton, Dickinson and Company) announced a $24 million investment from the U.S. Department of Defense and HHS to scale up U.S. manufacturing of the BD Veritor SARS-CoV-2 test, increasing production capacity by 50% to over 12 million test kits per month by February 2021.

BD inaugurated a new factory in Curitiba, Brazil, for BD Vacutainer vacuum blood collection tubes, with an investment of R$130 million and capacity of 150-200 million tubes per year, creating over 40 direct jobs.

BD (Becton Dickinson) has launched a new pre-filled syringe production project at its BD Rapid Diagnostics Products (Suzhou) facility in Suzhou Industrial Park, China. The project, with an investment of nearly $300 million, will have an annual capacity of 125 million units.

BD (Becton, Dickinson and Company) completed the acquisition of CR Bard, Inc., integrating Bard's 16,000 employees with BD's 65,000 employees, creating a combined company with approximately $16 billion in revenue.

BD is spending approximately $60 million on a 69,000-square-foot expansion and upgrade of its Columbus-East facility in Columbus, Nebraska, to create one of the largest plastic injection molding plants in the world. The project is expected to be completed by 2021.

BD (Becton, Dickinson and Company) plans to invest £172 million to build eight new manufacturing lines at its Plymouth site, creating 200 jobs over four years.

CareFusion (BD) announced a 442 million pesos ($21 million) investment in its Tijuana plant, creating 300 new jobs. The expansion includes transferring sub-assembly of 80 products to Tijuana, adding a 200,000 sq ft clean room, and injection molding and assembly lines.